Mylan: The Market Really, Really, Really Doesn’t Like the Meda Deal
February 11, 2016 at 12:30 PM EST
Shares of Mylan ( MYL ) have tumbled nearly 20% after the UK-based pharmaceutical company said it would buy Swedish drug maker Meda for $7.2 billion. Citigroup's Liav Abraham and Nick Nieland explain why they don't like the deal:
